Results 41 to 50 of about 319,040 (312)

Pharmacogenetics of Anticoagulants [PDF]

Human Genomics and Proteomics, 2010
Warfarin, acenocoumarol, and phenprocoumon are among the major anticoagulant drugs worldwide. Because of their low therapeutic index and serious adverse reactions (ADRs), their wide use, and their varying kinetics and pharmacogenetic dependence, it is of great importance to explore further possibilities to forecast the dose beyond conventional INR ...
Rane, Anders, Lindh, Jonatan D.
openaire   +2 more sources

Anticoagulant Rodenticides, Islands and Animal Welfare Accountancy

Animals, 2019
Anticoagulant rodenticides are used to manage rodents in domestic, municipal, agricultural, and conservation settings. In mammals and birds, anticoagulant poisoning causes extensive hemorrhagic disruption, with the primary cause of death being severe ...
Penny Fisher, Karl J. Campbell, Gregg R. Howald, Bruce Warburton   +3 more
doaj   +1 more source

First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects

Frontiers in Pharmacology, 2022
Background: Targeting factor XI (FXI) is a promising therapeutic strategy for the treatment and prevention of thrombosis without increasing the risk of bleeding. Here, we assessed the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SHR2285, a
Rui Chen, Xiaoduo Guan, Pei Hu, Yanli Dong, Yi Zhu, Tengfei Zhang, Jianjun Zou, Shuyang Zhang   +7 more
doaj   +1 more source

Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): Three‐month interim analysis results

Journal of Arrhythmia, 2019
Background Direct oral anticoagulants are the first‐line drugs for anticoagulation therapy in nonvalvular atrial fibrillation (NVAF). However, a real‐world, large‐scale, clinical study on edoxaban has not been performed.
Takeshi Yamashita, Yukihiro Koretsune, Mayumi Ishikawa, Kazuhito Shiosakai, Seiji Kogure   +4 more
doaj   +1 more source

A California Without Rodenticides: Challenges for Commensal Rodent Management in the Future

Human-Wildlife Interactions, 2019
Rodenticides are an essential tool in the integrated pest management of infestations of commensal rodents (Rattus norvegicus, R. rattus, and Mus musculus).
Niamh Quinn, Sylvia Kenmuir, Laura Krueger   +2 more
doaj   +1 more source

Safety and preliminary efficacy of argatroban plus dual antiplatelet therapy for acute mild to moderate ischemic stroke with large artery atherosclerosis

Brain and Behavior, 2022
Objective Previous studies suggest the benefit of dual antiplatelet therapy (DAPT) for acute ischemic stroke with large artery atherosclerosis (LAA) etiology, but there is no study about the effect of DAPT plus anticoagulant in this population. Methods A
Xiao‐Qiu Li, Xiao‐Wen Hou, Yu Cui, Xiao‐Fu Tian, Xin‐Hong Wang, Zhong‐He Zhou, Hui‐Sheng Chen   +6 more
doaj   +1 more source

Cancer and thrombosis: Managing the risks and approaches to thromboprophylaxis [PDF]

, 2006
Patients with cancer are at increased risk of venous thromboembolism (VTE) compared with patients without cancer. This results from both the prothrombotic effects of the cancer itself and iatrogenic factors, such as chemotherapy, radiotherapy, indwelling
Altinbas M, Athanasoulis CA, Bergqvist D, Bergqvist D, Buller HR, Clagett PG, Da Silva MS, Decousus H, ENOXACAN Study Group, Falanga A, Geerts WH, Gitter MJ, Goldenberg N, Gomes MPV, Green D, Haas S, Heit JA, Hettiarachchi RJK, Hull R, Hutten BA, International Multicentre Trial, Johnson MJ, Kakkar VV, Karthaus M, Koopman MMW, Levine MN, Mousa S A, Mousa SA, Prandoni P, Rasmussen MS, Rickles FR, Sallah S, Samama M, Siragusa B, The Columbus Investigators, White RH, Zacharski LR   +36 more
core   +1 more source

Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events [PDF]

, 2018
Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivaroxaban an factor Xa inhibitor.
Cafolla, Arturo, Chiarotti, Flavia, Dragoni, Francesco, Iori, Anna Paola, La Rocca, Ursula   +4 more
core   +1 more source

A combination of bioflavonoid, oral thrombolytic and anticoagulant in the treatment of thrombophlebitis of varicose veins in outpatient surgical practice

Амбулаторная хирургия
Introduction. Comparability of the outcomes of treatment of patients with thrombophlebitis of varicose veins using surgical intervention and medical therapy, a wide range of drugs have become the basis for conducting this study.Aim.
E. P. Krivoshchekov, A. V. Poseryaev, M. Yu. Khoroshilov, V. E. Romanov, B. M. Rakhimov, A. V. Kazantsev, S. Zh. Kirgizbaev   +6 more
doaj   +1 more source

Oral Anticoagulants in Women: What's the Difference? A Narrative Review

Clinical and Applied Thrombosis/Hemostasis
Gender sensitive medicine refers to the need to individualize epidemiology, diagnosis, knowledge of disease presentation, and therapy based also on sex and gender. An impressive amount of scientific literature deals now with sex and gender differences in
Elena Maria Faioni M.D, Barbara Scimeca M.D   +1 more
doaj   +1 more source